|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Anacor Pharmaceuticals, Inc.
| | | Phone: | (650) 543-7500 | Fax: | (650) 543-7660 | Year Established: | 2000 | Ticker: | PFE | Exchange: | NYSE | Main Contact: | Vince Ippolito, Executive VP & CCO | | Other Contacts: | Eric Easom, VP, Neglected Disease R&D Lee T. Zane, M.D., Senior VP & CMO Ryan T. Sullivan, Executive VP & General Counsel Paul L. Berns, President & CEO Graeme Bell, Executive VP & CFO
| | Company Description | Anacor (formerly AnaMax), a Pfizer company, is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. Anacor has focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. AN2690 is licensed to Schering-Plough under a worldwide development and commercialization agreement for all indications including the treatment of onychomycosis. Anacor also has a research and development collaboration with GlaxoSmithKline for the discovery, development, manufacture and worldwide commercialization of novel systemic therapeutics for viral and bacterial diseases utilizing Anacor's boron-based chemistry. | |
|
|
|
|
|